HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
about
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenAn HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells.Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents.The Impacts of Genome-wide Analyses on our Understanding of Human Herpesvirus Diversity and Evolution.Pharmacological Induction of Heme Oxygenase-1 Impairs Nuclear Accumulation of Herpes Simplex Virus Capsids upon Infection.US6 Gene Deletion in Herpes Simplex Virus Type 2 Enhances Dendritic Cell Function and T Cell Activation.Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study.An HSV-2 single-cycle candidate vaccine deleted in glycoprotein D, ΔgD-2, protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2.Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection
P2860
Q33663463-95E77710-B096-464D-8286-89D13171768FQ34549656-EA85520C-B4CE-49D4-91DE-F3C9F1E69E23Q38650844-E5C41329-7CBD-43A8-A61C-DB228E064768Q38998931-1155393F-F0F4-4874-8774-F6B2C4070118Q40067153-B12B8729-555F-4058-A4D5-BEF9D08E98A0Q40121437-0B48A39D-CA43-47AF-8C92-C5DCFA079361Q42778214-715DBB53-5509-4FBD-9829-2FE660A415FDQ44106381-B815D134-26E8-4685-92FD-B197CE2CAB2EQ45324219-A807ED62-9C45-428F-B0C9-A3B4D117A6BBQ47184537-AE856F07-5B01-4860-AB66-4233912AE322Q47319374-31BCAAAE-4CAC-4A0B-9A05-EA0A72CA14D2Q55406946-2E1A8DC3-A4D9-46F1-BB2E-D66E1C83C3A8Q57072187-7F57725D-1E48-494E-99CF-F562A057D65C
P2860
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@ast
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@en
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@nl
type
label
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@ast
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@en
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@nl
prefLabel
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@ast
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@en
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@nl
P2093
P2860
P1433
P1476
HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates
@en
P2093
Betsy C Herold
Christopher D Petro
Clare Burn
Nazanin Khajoueinejad
Rani Sellers
P2860
P356
10.1172/JCI.INSIGHT.88529
P577
2016-08-01T00:00:00Z